New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 22, 2017 – The FDA announced the approval of Genentech’s Rituxan Hycela (rituximab and hyaluronidase human) for adult patients with various forms of lymphoma and leukemia.
Download PDF
Return to publications
